Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn

Clicks: 346
ID: 120562
1997
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Respiratory syncytial virus immune globulin intravenous (RSV-IGIV) has been approved by the Food and Drug Administration for use in the prevention of severe RSV infections in infants and children younger than 24 months with bronchopulmonary dysplasia or a history of premature birth (< or = 35 wee …
Reference Key
1997pediatricsrespiratory Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;
Journal pediatrics
Year 1997
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/9093323
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine Infant newborn immunoglobulins intravenous / therapeutic use* respiratory syncytial virus infections / prevention & control* practice guideline guideline contraindications cost-benefit analysis human / immunology* respiratory syncytial virus heart defects premature pmid:9093323 bronchopulmonary dysplasia / therapy congenital intravenous / economics

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.